Natera, Inc.NTRA
NASDAQ • Healthcare
$198.50
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
+38.8% YoY
Gross Margin
64.8%
Health Score
6/10
D/E Ratio
0.13
Confidence
—
Business Snapshot
Natera is a genetic testing company serving the healthcare diagnostics market, with key products in non-invasive prenatal testing (Panorama, Horizon) and oncology liquid biopsy (Signatera). The company operates in the fast-growing precision medicine and cancer monitoring space, where it is a recognised leader in ctDNA-based minimal residual disease testing. With trailing twelve-month revenue of $2.50 billion, Natera is a large-revenue, high-growth firm that is not yet profitable on a net income basis. Its defining characteristic is a high gross margin (64.8%) combined with sustained investment in R&D and commercial expansion, which has produced strong top-line growth but negative net margins and a history of earnings losses.
Financial Health
Gross margin of 64.8% is healthy but has declined from 67.1% in the prior year, signalling modest margin compression. Net margin of -9.1% reflects continued operating losses, though this is an improvement from deeper losses in prior quarters...